News
KNSA
57.13
-2.41%
-1.41
Weekly Report: what happened at KNSA last week (0504-0508)?
Weekly Report · 4d ago
Kiniksa Pharmaceuticals announces annual shareholder meeting
PUBT · 6d ago
Kiniksa publishes 2025 annual report
PUBT · 6d ago
Why Kiniksa Pharmaceuticals (KNSA) Is Up 5.4% After Raising 2026 Revenue Guidance And What's Next
Simply Wall St · 05/06 03:30
Kiniksa CMO John F. Paolini disposes 58,424 shares for $3.15 million
PUBT · 05/05 21:15
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Strong Q1 Results And Raised Revenue Guidance
Simply Wall St · 05/05 01:33
Analysts Are Bullish on These Healthcare Stocks: Kiniksa Pharmaceuticals (KNSA), Kymera Therapeutics (KYMR)
TipRanks · 05/04 12:22
Weekly Report: what happened at KNSA last week (0427-0501)?
Weekly Report · 05/04 09:38
Kiniksa Pharmaceuticals CSO Resigns and Shifts to Advisor
TipRanks · 05/01 21:55
Kiniksa Chief Strategy Officer Eben Tessari resigns to pursue new role
PUBT · 05/01 20:34
Kiniksa CEO Sanj K Patel sells shares worth $2.62 million
PUBT · 05/01 20:33
Kiniksa CEO Sanj K Patel disposes of 486,339 shares for $25.23 million
PUBT · 04/30 22:33
Is It Too Late To Consider Kiniksa Pharmaceuticals (KNSA) After Its 91% One-Year Surge?
Simply Wall St · 04/30 15:12
Kiniksa Pharmaceuticals’ Mine Safety Disclosure: No Incidents Reported but Transparency Gaps Remain for Investors
TipRanks · 04/30 06:00
Kiniksa director Barry Quart sells 13,099 shares for $656,812.9
PUBT · 04/29 20:50
Kiniksa Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Dow Jones · 04/29 19:46
Kiniksa Pharmaceuticals Price Target Raised to $64.00/Share From $62.00 by Canaccord Genuity
Dow Jones · 04/29 19:46
Kiniksa Pharmaceuticals Price Target Raised to $60.00/Share From $50.00 by Citigroup
Dow Jones · 04/29 17:59
Kiniksa Pharmaceuticals Is Maintained at Buy by Citigroup
Dow Jones · 04/29 17:59
Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $60
Benzinga · 04/29 17:49
More
Webull provides a variety of real-time KNSA stock news. You can receive the latest news about Kiniksa Pharmaceuticals International, plc through multiple platforms. This information may help you make smarter investment decisions.
About KNSA
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.